BR0011708A - Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações - Google Patents

Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações

Info

Publication number
BR0011708A
BR0011708A BR0011708-0A BR0011708A BR0011708A BR 0011708 A BR0011708 A BR 0011708A BR 0011708 A BR0011708 A BR 0011708A BR 0011708 A BR0011708 A BR 0011708A
Authority
BR
Brazil
Prior art keywords
alkoxy
activity
compounds
treatment
compound
Prior art date
Application number
BR0011708-0A
Other languages
English (en)
Inventor
Carlo Farina
Stefania Gagliardi
Pietro A T Novella
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Publication of BR0011708A publication Critical patent/BR0011708A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

"DERIVADOS DE INDOL E SEU USO PARA O TRATAMENTO DE OSTEOPOROSE DENTRE OUTRAS APLICAçõES". Composto de fórmula ( I ), ou seu sal ou solvato, em que: R~ 1~ e R~ 2~ representarem cada um independentemente alcóxi C~ 1-6~ ou halo; R~ 3~ e R~ 4~ representarem cada um independentemente hidrogênio, alcóxi C~ 1-6~, aril alcóxi C~ 1-6~, hidróxi, carbóxi alcóxi C~ 1-6~, hidróxi alcóxi C~ 1-6~, diidróxi alcóxi C~ 1-6~, mono- e di(alquil C~ 1-6~) amino alcóxi C~ 1-6~, ou amino alcóxi C~ 1-6~, e R~ 5~ representar -NR~ s~R~ t~, em que R~ s~ e R~ t~ representam cada um independentemente hidrogênio, alquila C~ 1-6~ não substituída ou substituída, ou heterociclila não substituída ou substituída, processo para a preparação desse composto, composição farmacêutica contendo esse composto e o uso do composto ou composição em medicina. Compostos de indol particulares são seletivos para osteoclastos de mamíferos, agindo na inibição seletiva de sua atividade de reabsorção óssea. Esses compostos são, portanto, considerados particularmente úteis para o tratamento e/ou profilaxia de doenças associadas à perda de massa óssea, como osteoporose e doenças osteopênicas relacionadas, doença de Paget, hiperparatireoidismo e doenças relacionadas. Também se considera que esses compostos possuam atividade antitumoral, atividade antiviral ( por exemplo, contra os vírus Semliki Forest, da Estomatite Vesicular, da Doença de Newcastle, da Influenza A e B, HIV ), atividade antiúlcera ( por exemplo, os compostos podem ser úteis para o tratamento de gastrite crónica e úlcera péptica induzida por Helicobacter pylori ), atividade imunossupressora, atividade antilipidêmica, atividade antiaterosclerótica e úteis para o tratamento de AIDS e doença de Alzheimer. Além disso, esses compostos também são considerados úteis na inibição da angiogênese, isto é, a formação de novos vasos sang³íneos que é observada em vários tipos de estados patológicos ( doenças angiogênicas ), como artrite reumatóide, retinopatia diabética, psoríase e tumores sólidos.
BR0011708-0A 1999-06-18 2000-06-16 Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações BR0011708A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914371.1A GB9914371D0 (en) 1999-06-18 1999-06-18 Novel compounds
PCT/EP2000/005672 WO2001002388A1 (en) 1999-06-18 2000-06-16 Indole derivatives and their use for the treatment of osteoporosis amongst other applications

Publications (1)

Publication Number Publication Date
BR0011708A true BR0011708A (pt) 2002-05-21

Family

ID=10855696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011708-0A BR0011708A (pt) 1999-06-18 2000-06-16 Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações

Country Status (30)

Country Link
US (2) US6787550B1 (pt)
EP (1) EP1212317B1 (pt)
JP (1) JP2003503490A (pt)
KR (1) KR100701109B1 (pt)
CN (1) CN1179960C (pt)
AR (1) AR024390A1 (pt)
AT (1) ATE276245T1 (pt)
AU (1) AU768726B2 (pt)
BR (1) BR0011708A (pt)
CA (1) CA2376657A1 (pt)
CO (1) CO5200757A1 (pt)
CZ (1) CZ301697B6 (pt)
DE (1) DE60013859T2 (pt)
DK (1) DK1212317T3 (pt)
ES (1) ES2226870T3 (pt)
GB (1) GB9914371D0 (pt)
GC (1) GC0000341A (pt)
HK (2) HK1048468B (pt)
HU (1) HUP0202049A3 (pt)
IL (2) IL147012A0 (pt)
MX (1) MXPA01013277A (pt)
MY (1) MY129425A (pt)
NO (1) NO322313B1 (pt)
NZ (1) NZ516131A (pt)
PL (1) PL352964A1 (pt)
PT (1) PT1212317E (pt)
TR (1) TR200103683T2 (pt)
TW (1) TWI248440B (pt)
WO (1) WO2001002388A1 (pt)
ZA (1) ZA200200177B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2005009993A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
KR101242962B1 (ko) 2004-09-17 2013-03-13 아이데닉스 파마슈티칼스, 인코포레이티드 Ｈｉｖ 억제제로서의 포스포인돌
EP2813498B1 (en) * 2004-10-04 2016-04-20 Manfredi, John Compounds for Alzheimer's disease
US7833805B2 (en) * 2004-10-21 2010-11-16 University Of Cincinnati Selectively permeable membranes on porous substrates
WO2007010723A1 (ja) * 2005-07-20 2007-01-25 National University Corporation Kanazawa University トリプトファン誘導体及びその用途
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
RU2385865C2 (ru) * 2005-08-15 2010-04-10 Айрм Ллк Соединения и композиции в качестве миметиков тро
EP1779848A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
CA2637373A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US7820721B2 (en) 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007212104A1 (en) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009543805A (ja) * 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
WO2008042240A2 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as hiv inhibitors
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
MX2011008601A (es) 2009-02-16 2011-09-09 Giuliani Int Ltd Compuestos de alquilamido y usos de los mismos.
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
RS53844B1 (en) * 2010-09-08 2015-08-31 Bristol-Myers Squibb Company NEW PIPERAZINE ANALYSIS AS A WIDER ANTI-VIRUS MEDICINE AGAINST VIRUS INFLUENCE
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
US20120142627A1 (en) * 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
IN2014DN08157A (pt) 2012-04-18 2015-05-01 Nogra Pharma Ltd
KR20210125047A (ko) 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
CN113024432A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种氨磺必利药典杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
BR9606743A (pt) * 1995-01-10 1997-12-30 Smithkline Beecham Spa Derivados indol úteis no tratamento de osteoporose
ES2229375T3 (es) * 1996-07-09 2005-04-16 Nikem Research S.R.L. Derivados del indol para el tratamiento de la osteoporosis.
ATE288909T1 (de) * 1997-12-24 2005-02-15 Nikem Research Srl Indolderivate verwendbar zur behandlung von u.a. osteoporosis

Also Published As

Publication number Publication date
AU768726B2 (en) 2004-01-08
CZ20014496A3 (cs) 2002-07-17
MXPA01013277A (es) 2002-06-04
DE60013859T2 (de) 2005-09-29
CZ301697B6 (cs) 2010-05-26
KR100701109B1 (ko) 2007-03-29
ZA200200177B (en) 2003-09-23
ATE276245T1 (de) 2004-10-15
PL352964A1 (en) 2003-09-22
HK1049164A1 (zh) 2003-05-02
IL147012A (en) 2007-06-03
CN1370159A (zh) 2002-09-18
TR200103683T2 (tr) 2003-01-21
HK1048468A1 (en) 2003-04-04
CO5200757A1 (es) 2002-09-27
US6787550B1 (en) 2004-09-07
HUP0202049A2 (hu) 2002-11-28
CN1179960C (zh) 2004-12-15
PT1212317E (pt) 2005-02-28
EP1212317A1 (en) 2002-06-12
NO322313B1 (no) 2006-09-11
NO20016149L (no) 2001-12-17
HUP0202049A3 (en) 2003-12-29
JP2003503490A (ja) 2003-01-28
DE60013859D1 (de) 2004-10-21
CA2376657A1 (en) 2001-01-11
TWI248440B (en) 2006-02-01
IL147012A0 (en) 2002-08-14
MY129425A (en) 2007-03-30
AR024390A1 (es) 2002-10-02
GB9914371D0 (en) 1999-08-18
DK1212317T3 (da) 2005-01-24
ES2226870T3 (es) 2005-04-01
EP1212317B1 (en) 2004-09-15
NO20016149D0 (no) 2001-12-17
WO2001002388A1 (en) 2001-01-11
US20040235930A1 (en) 2004-11-25
NZ516131A (en) 2003-10-31
GC0000341A (en) 2007-03-31
HK1048468B (zh) 2005-07-29
KR20020025079A (ko) 2002-04-03
AU5816500A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
BR0011708A (pt) Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações
ATE33653T1 (de) Antivirale purinderivate.
PT88255A (pt) Processo para a preparacao de derivados do indole
NO933450L (no) Antiarrytmiske og kardiobeskyttende substituerte 1(2H)isokinoliner, fremgangsmåter for deres fremstilling, medikament inneholdende disse og anvendelse derav for fremstilling av et medikament for å bekjempe hjertefeil
DE3570437D1 (en) 1-hydroxy-1,1-diphosphonic-acid derivatives, process for their preparation and pharmaceutical preparations, especially for the treatment of bone tumours
HUP0002754A2 (hu) (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek
BR9914453A (pt) Cristal de tetrafosfato de diuridina ou seu sal, método de sua preparação e método de produção do mencionado composto
DK158663C (da) 6-substituerede 2-methylpyridiner og farmaceutiske praeparater indeholdende saadanne
IT1169783B (it) Derivati dell' acido 4-fenil 4-osso-buten 2-oico, loro procedimento di preparazione e loro applicazione come prodotti medicinali
DE69004989D1 (de) Indolderivate.
TW306924B (pt)
PT88088A (pt) Processo para a preparacao de derivados de piperidina e de composicoes farmaceuticas que os contem
GEP19960471B (en) Method of producing n-sulfamine-3-(2-guanidinethiazol-4-ylmethylthio)-propioneamidine
BR9810622A (pt) 3-benzilpiperidinas
Ogston Specificity of the enzyme aconitase
ES528455A0 (es) Procedimiento de preparacion de nuevos derivados de piperidina y sus sales de adicion acidas y amonicas cuaternarias
FI910159A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 9a-hydroxi-3-oxo-4,24(25)-stigmastadien-26 -syraderivat.
BR0002686A (pt) Processos e intermediários
BR9908864A (pt) Processo para preparação de derivados de nitroguanidina
GB952891A (en) Guanidino compounds and method of producing the same

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NIKEM RESEARCH S.R.L. (IT)

Free format text: TRANSFERIDO DE: GLAXOSMITHKLINE S.P.A.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.